Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension

Pulmonary Hypertension Due to Left Heart Disease Clinical Trial

Official title:
Comparative Study Between Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension Undergoing Cardiac Surgery

Status Recruiting

Clinical Trial Summary

The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery

Clinical Trial Description

Milrinone is widely used in cardiac surgery as an inotrope and pulmonary vasodilator agent But , intravenous milrinone has been associated with systemic hypotension and increased requirement for vasoactive drugs The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery ;

Study Design

Related Conditions & MeSH terms

Heart Diseases
Hypertension
Hypertension, Pulmonary
Pulmonary Hypertension Due to Left Heart Disease

Clinical Trial Details

NCT number	NCT04484675
Study type	Interventional
Source	Zagazig University
Contact	Heba M EL-Asser, MD
Phone	01062393152
Email	aseelaswad1@yahoo.com
Status	Recruiting
Phase	Phase 4
Start date	January 20, 2022
Completion date	February 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06048120` - A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)	Phase 1
Recruiting	`NCT02164526` - Registry for Pulmonary Hypertension Due to Left Heart Disease in China	N/A
Not yet recruiting	`NCT05464238` - Training in HFpEF-PH	N/A
Recruiting	`NCT04808596` - Pulmonary Hypertension Biorepository and Registry
Withdrawn	`NCT04882774` - Telemonitoring to Treat Group 2 Pulmonary Hypertension	Phase 2